Key result
Despite differing in vitro potassium channel function, LQT1 mutations Y111C and R518X showed no significant differences in in vivo electrophysiological properties other than a longer QTc in Y111C.
Why the study?
Do electrophysiological phenotypes assessed by vectorcardiography differ between specific LQT1 mutations (Y111C, R518X), LQT2 mutations, and healthy controls?
Observational (n=239)
Do electrophysiological phenotypes assessed by vectorcardiography differ between specific LQT1 mutations (Y111C, R518X), LQT2 mutations, and healthy controls?
There is a marked discrepancy between in vitro potassium channel function and in vivo electrophysiological properties in LQT1 mutations, suggesting caution in predicting clinical risk based solely on in vitro ion channel assessment.
May warrant caution extrapolating in vitro LQT1 data to clinical risk; leaves open mutation-specific in vivo phenotyping for risk stratification.
Long QT syndrome is the prototypical disorder of ventricular repolarization (VR), and a genotype-phenotype relation is postulated. Furthermore, although increased VR heterogeneity (dispersion) may be important in the arrhythmogenicity in long QT syndrome, this hypothesis has not been evaluated in humans and cannot be tested by conventional electrocardiography. In contrast, vectorcardiography allows assessment of VR heterogeneity and is more sensitive to VR alterations than electrocardiography. Therefore, vectorcardiography was used to compare the electrophysiological phenotypes of two mutations in the LQT1 gene with different in vitro biophysical properties, and with LQT2 mutation carriers and healthy control subjects. We included 99 LQT1 gene mutation carriers (57 Y111C, 42 R518X) and 19 LQT2 gene mutation carriers. Potassium channel function is in vitro most severely impaired in Y111C. The control group consisted of 121 healthy subjects. QRS, QT, and T-peak to T-end (Tp-e) intervals, measures of the QRS vector and T vector and their relationship, and T-loop morphology parameters were compared at rest. Apart from a longer heart rate-corrected QT interval (QT heart rate corrected according to Bazett) in Y111C mutation carriers, there were no significant differences between the two LQT1 mutations. No signs of increased VR heterogeneity were observed among the LQT1 and LQT2 mutation carriers. QT heart rate corrected according to Bazett and Tp-e were longer, and the Tp-e-to-QT ratio greater in LQT2 than in LQT1 and the control group. In conclusion, there was a marked discrepancy between in vitro potassium channel function and in vivo electrophysiological properties in these two LQT1 mutations. Together with previous observations of the relatively low risk for clinical events in Y111C mutation carriers, our results indicate need for cautiousness in predicting in vivo electrophysiological properties and the propensity for clinical events based on in vitro assessment of ion channel function alone.
No takes yet. Share an insight, caveat, or question.
Diamant et al. (2013) conducted an observational in Long QT syndrome (n=239). LQT1 and LQT2 gene mutations vs. Healthy control subjects was evaluated on Electrophysiological phenotypes including QRS, QT, and Tp-e intervals, and vectorcardiography parameters. Despite differing in vitro potassium channel function, LQT1 mutations Y111C and R518X showed no significant differences in in vivo electrophysiological properties other than a longer QTc in Y111C.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: